3D printed vasculature, Antibody Discovery Platform

Prellis Biologics is at the forefront of antibody discovery through its innovative EXIS™ platform, which integrates human immune biology with advanced technologies. The platform utilizes 3D bioprinted lymph node organoids (LNO™) to replicate the complex processes of the human immune system in vitro. By harnessing the genetic diversity from multiple blood donors, Prellis can access a vast repertoire of fully human antibodies, significantly reducing the risk of immunogenicity. This approach allows for the rapid generation of diverse antibody candidates, which are essential for developing next-generation therapeutics.

The company employs a synergistic methodology that combines machine learning with traditional lab techniques to enhance the efficiency of antibody screening and optimization. Through AI-guided screening, Prellis can analyze and predict the most promising antibody candidates from a large library generated during the B-cell activation process. This iterative cycle of AI predictions and experimental validation not only streamlines the discovery process but also ensures the development of highly specific antibodies with low immunogenicity risk, paving the way for transformative therapeutic solutions.

United States

Prellis Bio is hiring Immunologists! We are expanding our Externalized Immune System, EXIS™, platform with applications in antibody discovery, immunogenicity, and vaccine screening all in the same platform. Prellis Biologics, Inc. is a privately held company based in the San Francisco Bay Area, CA. Apply at www.prellisbio.com.


Prellis Biologics

Company Details